From the Journals

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Share

A global pharmacovigilance analysis of over 30 million reports revealed that the higher-dose 2.4-mg weekly formulation of semaglutide (Wegovy) is linked to a markedly increased risk of ischemic optic neuropathy (ION) compared to the lower-dose formulation (Ozempic). The risk was approximately 4.7 times higher in Wegovy, particularly among men. The study, led by Moiz Lakhani from the University of Ottawa, emphasized the need for personalized therapy and further studies to ascertain a causal relationship, as current data cannot establish incidence.

Original Source(s)

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

  • by Kerri Miller

  • March 11, 2026

  • 5 min

Related Content

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • March 12, 2026

  • 5 min
The Most Influential Conversations in Ophthalmology Aren’t on the Podium

How WhatsApp is quietly shaping clinical practice